Cullinan Therapeutics (CGEM) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Entera Bio (ENTX) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 30.6% versus a loss of 6.1%. Over five years, ENTX leads with a -3.6% price change compared with -51.2% for CGEM. Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $575.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | ENTX |
|---|---|---|
| Share price | $8.89 | $3.31 |
| Market cap | $577.15M | $575.53M |
| 1-day change | -1.98% | +0.76% |
| YTD return | -14.11% | +70.36% |
| 1-year return | -6.12% | +30.63% |
| 5-year return | -51.21% | -3.64% |
| EPS (TTM) | $-3.09 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.00K |
| Revenue growth (YoY) | — | -76.80% |
| Net income (latest FY) | $-219.88M | $-11.44M |
| Gross margin | — | 0.00% |
| Operating margin | — | -27450.00% |
| Net margin | — | -27235.71% |
| 52-week high | $23.19 | $4.20 |
| 52-week low | $8.47 | $0.91 |
| Distance from 52-week high | -61.66% | -21.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +285.49% | +195.01% |
| Average volume | 997.14K | 438.35K |
| Shares outstanding | 64.92M | 174.14M |
| Employees | 109 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed CGEM by 36.8 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
CGEM vs ENTX FAQ
Which is bigger, Cullinan Therapeutics or Entera Bio?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $575.53M for Entera Bio (ENTX).
Which stock has performed better over the past year, CGEM or ENTX?
ENTX returned +30.63% over the past 12 months, compared with -6.12% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.